Behind the scenes of a billion dollar pharma deal

On 9 June 2020 Eli Lilly and Evox Therapeutics inked a neuroscience therapy deal worth $1.2 billion.

In this webinar two of the key players in that deal will take you behind-the-scenes to explain how Evox got on Lilly’s radar, explore the challenges of forming a partnership under a COVID-19 lockdown, and recall the discussions and internal debates that led to one of the biggest biopharma deals of the year so far.

Go behind the scenes with:

Raymond Jordt

Former Vice President of Corporate Business Development at Eli Lilly

Simon Dew

Former Vice President of Business Development at Evox Therapeutics